SS-31 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of SS-31 is approximately 20-30 minutes. This means dosing daily subcutaneous or weekly IV infusion is typical to maintain stable levels. The half-life directly affects how long SS-31 remains active and influences optimal injection timing.
What Is the Half-Life of SS-31?
The half-life of SS-31 is approximately 20-30 minutes. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer SS-31 to maintain therapeutic blood levels.
What Does SS-31's Half-Life Mean for Dosing?
With a half-life of approximately 20-30 minutes, SS-31 requires dosing daily subcutaneous or weekly IV infusion to maintain stable levels. The standard dosage of 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV via subcutaneous injection or intravenous infusion accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, SS-31 reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For SS-31, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject SS-31?
Optimal timing depends on your research goals. A half-life of approximately 20-30 minutes means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (daily subcutaneous or weekly IV infusion) for more stable levels throughout the day.
How Does SS-31's Half-Life Compare to Similar Peptides?
SS-31 is a Mitochondrial-targeting tetrapeptide. Its half-life of approximately 20-30 minutes positions it with a shorter duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your SS-31 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for SS-31.
Open Calculator →Bottom Line: SS-31 Half-Life and Dosing
SS-31 has a half-life of approximately 20-30 minutes, supporting the standard protocol of 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV dosed daily subcutaneous or weekly IV infusion over 12-48 weeks in clinical trials.
Read our SS-31 dosage guide for complete protocol details.
Complete Guide
SS-31 (Elamipretide) : Mitochondrial Peptide for Energy & Aging
Related Reading
- SS-31 Dosage Guide
- SS-31 Benefits
- SS-31 Side Effects
- SS-31 Stacking Guide
- SS-31 Cycle Guide
- SS-31 Research
Research-Grade Sourcing
If you're going to research SS-31, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What is the recommended SS-31 dosage?
Common dosages: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Cycle length: 12-48 weeks in clinical trials. Half-life: approximately 20-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Is SS-31 safe?
SS-31 has shown a favorable safety profile in research. FDA-approved September 2025 (FORZINITY) for Barth syndrome. Phase 3 trials ongoing for other indications. All research should follow appropriate safety protocols.